Xanthine oxidase-IN-6_product_DataBase

Bioactivity	Xanthine oxidase-IN-6 (Compound 6c) is a potent, orally active, mixed-type xanthine oxidase (XOD) inhibitor with an IC50 value of 1.37 µM. Xanthine oxidase-IN-6 shows strong anti-hyperuricemia and renal protective activity[1].
Invitro	Xanthine oxidase-IN-6 (Compound 6c) is a mixed-type XOD inhibitor, preferentially bound to the free enzyme and not the enzyme substrate complex[1].Xanthine oxidase-IN-6 is stable in simulated gastrointestinal digestion, with hydrolysis half-life more than 4 h[1].Xanthine oxidase-IN-6 (0-100 µM) exhibits an obvious anti-inflammatory effect by reducing the level of inflammatory factors (TGF-β, TNF-α and IL-1β) in a dose-dependent manner[1].Xanthine oxidase-IN-6 (0-100 µM, 48 h) inhibits HK-2 cell epithelial mesenchymal transition under high level of uric acid[1]. Western Blot Analysis[1] Cell Line:
In Vivo	Xanthine oxidase-IN-6 (Compound 6c) (0-20 mg/kg; i.g.; once daily for 2 weeks) shows anti-hyperuricemic effects, alleviates kidney damage, and inhibits XOD activity in a dose-dependent manner[1].Xanthine oxidase-IN-6 (0-20 mg/kg; i.g.; once daily for 2 weeks) effectively reduces renal fibrosis and inflammation[1]. Animal Model:
Name	Xanthine oxidase-IN-6
Formula	C29H34N2O15
Molar Mass	650.58
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Jia-shu Chen, et al. Synthesis and biological evaluation of geniposide derivatives as inhibitors of hyperuricemia, inflammatory and fibrosis. Eur J Med Chem. 2022 Apr 20;237:114379.

PeptideDB

Xanthine oxidase-IN-6

CAS: F: C29H34N2O15 W: 650.58